ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction

Thursday, September 25, 2014

Submitted by

Mark Ferguson

Source

Source Name: Journal of Clinical Oncology

Source URL: http://jco.ascopubs.org/content/32/27/2983?cmpid=jco_etoc_20September2014

Author(s)

Andrew R. Davies, James A. Gossage, Janine Zylstra, Fredrik Mattsson, Jesper Lagergren, Nick Maisey, Elizabeth C. Smyth, David Cunningham, William H. Allum and Robert C. Mason

This retrospective review evaluated the relationship of pretreatment vs post-induction therapy stage to survival in patients undergoing surgery for esophageal adenocarcinoma in 2 centers in London. Among 584 pts, 400 underwent induction therapy. Downstaging predicted improved survival (HR 0.43). Downstaging was associated with decreased rates of local and distant recurrence. Survival was more closely associated with stage after induction therapy than initial stage.